Free Trial
Priyanka Grover

Priyanka Grover Analyst Performance

Vice President, Biotechnology Equity Research at JPMorgan Chase & Co.

Priyanka Grover is a stock analyst at JPMorgan Chase & Co. in the medical sector, covering 2 publicly traded companies. Over the past year, Priyanka Grover has issued 3 stock ratings, including buy and hold recommendations. While full access to Priyanka Grover's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Priyanka Grover's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
4 Last 1 Years
Buy Recommendations
75.00% 3 Buy Ratings
Companies Covered
2 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy75.0%3 ratings
Hold25.0%1 ratings
Sell0.0%0 ratings

Out of 4 total stock ratings issued by Priyanka Grover at JPMorgan Chase & Co., the majority (75.0%) have been Buy recommendations, followed by 25.0% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
2 companies

Priyanka Grover, an analyst at JPMorgan Chase & Co., currently covers 2 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
2 companies
100.0%

Priyanka Grover of JPMorgan Chase & Co. specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - DRUGS
1 company
50.0%
MED - BIOMED/GENE
1 company
50.0%

Priyanka Grover's Ratings History at JPMorgan Chase & Co.

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
4/30/2026Lower Price Target$3.46$10.00Overweight
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
3/23/2026Reiterated Rating$0.34Neutral
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
8/25/2025Boost Price Target$1.81$8.00Overweight
Mereo BioPharma Group plc - Sponsored ADR stock logo
MREO
Mereo BioPharma Group
3/27/2025Initiated Coverage$2.37$7.00Overweight